Patients with type 2 diabetes mellitus (T2DM) have reduced platelet inhibition compared with non-diabetics following P2Y 12 receptor blockade. Whether inhibition of P2Y 12 signalling can be enhanced by adjunctive treatment with cilostazol in T2DM patients is unknown. The aim of this pilot study was to assess the functional impact of cilostazol in T2DM patients on standard aspirin and clopidogrel treatment.
reduced cAMP levels thus contributing to their lower degree of platelet inhibition compared with non-diabetics following treatment with P2Y 12 receptor antagonists. 1 -4,7 -9 These laboratory findings may explain why diabetic patients have an enhanced risk of ischaemic events, including stent thrombosis, despite the use of clopidogrel 10 -14 and suggest the need for more aggressive and/or tailored antiplatelet treatment regimens in these high-risk patients. 8 Given the site of dysregulation of intraplatelet signalling, we hypothesized that intervening on pathways that increase cAMP levels can augment VASP-P and enhance inhibition of P2Y 12 signalling in T2DM patients.
Cilostazol is an inhibitor of phosphodiesterase 3 (PDEIII) and leads to an increase in intraplatelet cAMP levels. 15 In patients undergoing coronary stenting, treatment with cilostazol in adjunct to aspirin and thienopyridine therapy ('triple antiplatelet therapy') has been associated with a reduced risk of stent thrombosis and major adverse cardiac events compared with standard dual antiplatelet therapy. 16 -19 Importantly, cilostazol has been shown to be particularly effective in diabetic patients. 20 -23 The ever raising concerns of stent thrombosis in the current era of drug-eluting stents (DESs) has led to a more diffuse use of cilostazol in adjunct to standard aspirin and clopidogrel therapy, particularly in high-risk patients. However, whether treatment with cilostazol enhances inhibition of P2Y 12 receptor signalling remains unknown. The aim of this pilot study was to evaluate the functional impact of adjunctive treatment with cilostazol in T2DM patients with coronary artery disease (CAD) on standard dual antiplatelet therapy. Our hypothesis was that the adjunctive use of cilostazol will lead to enhanced P2Y 12 inhibition compared with standard dual antiplatelet therapy in these high-risk patients.
Methods

Patient population and study design
Patients were eligible for the study if they had T2DM, either on insulin or oral hypoglycaemic medication, and were between the age of 25 and 80 years. T2DM was defined according to the World Health Organization Report. 7, 24 All patients included had documented CAD, as all patients had previously undergone PCI, and were in a steady-state phase of clopidogrel treatment (75 mg/daily). Since pharmacokinetic and pharmacodynamic profiles vary markedly in the initial days or weeks after initiation of dual antiplatelet therapy, 6 patients had to be in their maintenance phase of treatment for at least 30 days to be included. All patients were also treated with low-dose aspirin (81 mg/daily). This dose of aspirin was chosen in order to reduce bleeding risk in patients on dual antiplatelet therapy. 25 Major exclusion criteria included: known allergies to aspirin, clopidogrel or cilostazol; impaired glucose tolerance or T2DM without pharmacological treatment, gestational diabetes, or transient hyperglycaemia; left ventricular ejection fraction ,35%; blood dyscrasia; serum creatinine level .2 mg/dL; active bleeding or bleeding diathesis; gastrointestinal bleed within last 6 months haemodynamic instability; cerebrovascular accident within 3 months; any malignancy; concomitant use of other antithrombotic drugs (oral anticoagulants, dypiridamole, ticlopidine) or non-steroid anti-inflammatory drugs; recent treatment (,30 days) with a glycoprotein IIb/IIIa antagonist; platelet count ,100 Â 10 6 /mL; haematocrit ,25%; liver disease (bilirubin level .2 mg/dL).
The study complied with the Declaration of Helsinki, was approved by the Institutional Review Board of the University of Florida College of Medicine-Jacksonville, and all patients gave their informed written consent. Since in the present study cilostazol was used for an indication non-approved by the Food and Drug Administration (FDA), an independent data safety monitoring committee was instituted for adjudication of adverse clinical events. The authors had full access to the data and take full responsibility for its integrity. All authors have read and agreed to the manuscript as written.
The OPTIMUS-2 (Optimizing anti-Platelet Therapy In diabetes MellitUS) study was a prospective, double-blind, double-dummy, placebocontrolled, randomized, cross-over platelet function study of patients with T2DM and CAD. Patients were recruited from the outpatient cardiology clinic of our hospital. Patients were assigned to receive cilostazol 100 mg or placebo tablets twice daily for 14 days and afterwards crossed-over treatment assignments for another 14 days. There was no wash-out phase between the two treatment periods. Placebo and treatment tablets were provided by Otsuka pharmaceuticals (Tokyo, Japan). Randomization and blinding were carried out by our division's pharmacy that computer-generated the randomization sequence and blindly dispensed the study medication and placebo. After determining eligibility and obtaining consent, the patient's study number was sent to the division's pharmacy and then the patient was randomized to one of two different sequence groups: placebo/cilostazol or cilostazol/placebo. Investigators and patients were blinded to treatment assignments. Placebo and treatment tablets were identical in size, colour, shape, and weight, and placed in standard medicine bottles. Each bottle was dispensed individually by the research coordinator at the appropriate patient visit. Unblinding was done at the end of the study. Platelet function was performed at three time points: (i) at baseline (before randomization); (ii) 14 days after randomization; (iii) 14 days after cross-over. Patient compliance to antiplatelet treatment was assessed by interview and pill counting. The flow-diagram of the study is shown in Figure 1 . The mechanism of action of cilostazol and how this may modulate P2Y 12 signalling, thus supporting our study hypothesis, is illustrated in Figure 2 .
Primary endpoint and sample size calculation
The primary endpoint of this study was the P2Y 12 reactivity index (PRI) achieved following treatment with cilostazol. Using a power analysis for paired testing, we hypothesized a 15% mean reduction in the primary endpoint following treatment with cilostazol compared with placebo with a standard deviation of the differences between the two groups to be 16%. Thus, 17 patients per group would be required to provide a 90% power to detect a statistical difference between groups with a two-sided a-level of 0.05. Estimation of platelet function values was based on our previous data in T2DM patients; 7 in particular, more aggressive antiplatelet therapy showed a 15% reduction in PRI. 
Blood sampling
Blood sampling for platelet function analyses were collected from an antecubital vein using a 21-gauge needle 2 -4 h after intake of aspirin, clopidogrel, and cilostazol/placebo. The first 2 -4 mL of blood were discarded to avoid spontaneous platelet activation. Samples were processed within 1 h after blood drawing by operators blind to patient's treatment assignment. Laboratory personnel were also blinded to treatment assignments. 
VerifyNow assay
The VerifyNow TM assay (Accumetrics, Inc., San Diego, CA, USA) is a rapid whole-blood point-of-care and was utilized according to the instructions of the manufacturer. 27, 28 The VerifyNow TM P2Y 12 assay reports the results as P2Y 12 reaction units (PRU). This assay mimics turbidometric aggregation and utilizes disposable cartridges containing 20 mM ADP and 22 nM PGE 1 . Aggregation testing using ADP as a sole agonist activates P2Y 1 and P2Y 12 purinergic signalling, while adding PGE 1 increases the specificity of the test for P2Y 12 signalling. 29 In a separate channel of the cartridge in which iso-TRAP is used as an agonist, a baseline value for platelet function is obtained, enabling assessment of platelet inhibition without having to wean the patient off antiplatelet treatment. Sensitivity to aspirin was evaluated using the VerifyNow system by means of dedicated cartridges containing arachidonic acid.
Results are expressed as aspirin reaction units (value !550 indicates aspirin responsiveness). 
Light transmittance aggregometry
Platelet aggregation was performed using light transmittance aggregometry (LTA) according to standard protocols. 1 -2,7 In brief, platelet aggregation was assessed using platelet-rich plasma (PRP) by the turbidimetric method in a two-channel aggregometer (Chrono-Log 490 Model, Chrono-Log Corp., Havertown, PA). PRP was obtained as a supernatant after centrifugation of citrated blood at 800 r.p.m. for 10 min. The isolated PRP was kept at 378C before use. Platelet-poor plasma (PPP) was obtained by a second centrifugation of the blood fraction at 2500 r.p.m. for 10 min. Light transmission was adjusted to 0% with PRP and to 100% for PPP for each measurement and assessed following challenge with ADP (5 and 20 mmol/L) in the presence and absence of PGE 1 (5 nM). Similar to the VASP-P and VerifyNow P2Y 12 assays, PGE 1 was added to the LTA assay to make the test more reflective of P2Y 12 signalling. 29 The concentration of PGE 1 chosen was that used in correlation analysis between LTA and the VerifyNow P2Y 12 assay which served for FDA approval of the latter device. Curves were recorded for 6 min. Aggregation was measured at peak (Agg max ) and at 5 min (Agg late ). 7 Inhibition of platelet aggregation (IPA) was defined as the percent decrease in Agg max and Agg late values. 7 Percentage of platelet disaggregation (D) between
Agg max and Agg late values was defined as: D (%)¼100 Â (1 2 Agg late /Agg max ). 7 Arachidonic acid-induced platelet aggregation was also performed in order to assess compliance and responsiveness to aspirin, defined as Agg max ,20% following 1 mmol/L arachidonic acid stimuli. The a i subunit leads to inhibition of adenylyl cyclase (AC), which reduces cyclic adenosine monophosphate (cAMP) levels. The decrease in cyclic adenosine monophosphate production reduces the activation of specific protein kinases (PKA), which in turn decreases phosphorylation (P) of vasodilator-stimulated phosphoprotein (VASP) leading to increased platelet activation and aggregation; the subunit b g activates kinases which induce granule secretion. Prostaglandin E 1 (PGE 1 ) activates adenylyl cyclase which increases cyclic adenosine monophosphate levels and VASP-P. Following hepatic metabolism, the active metabolite of clopidogrel irreversibly inhibits the P2Y 12 receptor, increasing cyclic adenosine monophosphate levels and VASP-P. Cilostazol increases cyclic adenosine monophosphate levels by means of PDEIII inhibition, potentially modulating VASP-P and intraplatelet P2Y 12 signalling. Type 2 diabetes mellitus patients have upregulation of P2Y 12 signalling secondary to low cyclic adenosine monophosphate levels, therefore making platelets of these patients a target to test for the effects of cilostazol on modulating receptor signalling. Solid arrows indicate activation. Dotted arrows indicate inhibition.
Statistical analysis
Categorical variables are expressed as frequencies and percentages. Continuous variables are presented as mean+SD. Continuous variables were analysed for a normal distribution with the ShapiroWilks goodness-of-fit test (using P-value ,0.1 as threshold). Only patients who successfully completed at least one treatment phase of the study were considered for comparisons. Paired t-tests were used for comparison of normally distributed continuous variables in the same group. Wilcoxon tests were used for paired comparisons of continuous variables not following a normal distribution. Treatment effects were evaluated comparing the functional parameters observed in the overall patient population after cilostazol treatment with those achieved after placebo regardless of the sequence in which patients received either cilostazol or placebo. The absolute between-treatment mean differences and 95% confidence intervals (CI) for the functional endpoints specific to P2Y 12 receptor signalling were then estimated in the two groups. In addition, in order to perform an unbiased estimation of the treatment effect, period and sequence effects, which may occur in crossover studies, were evaluated. To test for sequence treatment effects, we evaluated the functional endpoints within the two treatment sequences in which patients received either cilostazol or placebo. In particular, we compared the pre-crossover with the post-crossover functional values within the treatment sequence in which patients were randomized to placebo first and then cilostazol, and within the other sequence in which patients were randomized to cilostazol first and then placebo. Then, the absolute mean differences between the pre-crossover and the post-crossover values and comparisons of these between-treatment differences achieved in each sequence were computed. To test for period effects, for each sequence the average of the difference of the two periods and the sum of these two averages were calculated and then these two achieved averages of each sequence were compared. A P-value ,0.05 was considered statistically significant. Statistical analysis was performed using a SPSSv14.0 software (SPSS Inc., Chicago, IL).
Results
A total of 25 patients were randomized. Baseline demographics and clinical characteristics of randomized patients are shown in Table 1 . Following randomization, a total of five patients withdrew from the study within 48-72 h due to the development of side effects. Side effects leading to study drug discontinuation included headaches, gastrointestinal symptoms, and tachycardia. These occurred in four patients treated with cilostazol and in one treated with placebo. Similar side effects, but of lower severity not leading to withdrawal of study medication, occurred in three patients treated with cilostazol and in one patient treated with placebo. Therefore, a total of 20 patients were available to test for the study hypothesis ( Figure 1 ). There were no differences in baseline demographics between patients who did and did not complete the study protocol (data not shown). During the study period, there were no changes in medical therapy, including T2DM medications or anti-anginal therapy. There were no bleeding complications or other serious adverse events during the study. At all three study visits, all randomized patients were compliant and sensitive to aspirin based on LTA assessments (arachidonic-acid-induced aggregation ,20%). At all three study visits, using the VerifyNow aspirin assay, all randomized patients had ARU values ,550 except for one patient who had an ARU above this value at only one time point. Significantly lower PRI values were observed following treatment with cilostazol vs. placebo (P ¼ 0.0002; primary endpoint; Figure 3 ). The absolute between-treatment difference of PRI was 23.6 (95% CI, 14.1-33.2). In the sequence in which patients (n ¼ 11) were randomized to placebo first and then cilostazol, the pre-crossover PRI value was 59.6 + 17.7 and the postcrossover value was 31.6 + 17.7, resulting in a significant reduction in PRI crossing from placebo to cilostazol (P ¼ 0.001). In the sequence in which patients (n ¼ 9) received cilostazol first and then placebo, the pre-crossover PRI value was 42.4 + 21.2 and the post-crossover value was 60.3 + 14.7, resulting in a significant increase in PRI crossing from cilostazol to placebo (P ¼ 0.008). The comparison of absolute between-treatment differences in PRI measurements for each treatment sequence was not significant (P ¼ 0.23). Also, no period effect was observed (P ¼ 0.68). Flow cytometric assessment of VASP-P content was significantly higher following treatment with cilostazol vs. placebo (P ¼ 0.0001; Figure 4 ). Using the VerifyNow P2Y 12 assay, P2Y 12 inhibition (P ¼ 0.0001) and PRU values (P ¼ 0.002) were significantly higher and lower, respectively, following treatment with cilostazol vs. placebo ( Figure 5) .
LTA parameters more specific to P2Y 12 signalling by using PGE 1 in combination with ADP showed significantly lower platelet reactivity values following treatment with cilostazol compared with placebo, while no differences were observed between treatment groups using ADP as a sole agonist ( Table 2) . Accordingly, treatment with cilostazol led to a significant increase in IPA for all LTA parameters using PGE 1 in combination with ADP (P , 0.0001). Platelet disaggregation was also increased with cilostazol therapy compared with placebo (ADP 20 mmol/LþPGE 1 : 64+ 21 vs. 35 + 23%, P , 0.0001; ADP 5 mmol/LþPGE 1 : 72 + 18 vs. 56 + 27%, P ¼ 0.02). The absolute between-treatment mean differences and 95% CI for the endpoints specific to P2Y 12 signalling are summarized in Table 3 . As observed with the primary endpoint (PRI), no significant sequence and period effects were found for all evaluated secondary endpoints (data not shown).
Discussion
This platelet function study confirms the hypothesis that adjunctive treatment with cilostazol in a high-risk group of patients with T2DM and CAD already on standard dual antiplatelet therapy enhances inhibition of P2Y 12 receptor-related signalling. This was corroborated by multiple functional assessments, including flow cytometry, LTA, and a point-of-care device, evaluating this platelet signalling pathway. These findings may explain the better clinical outcomes in patients undergoing coronary stenting treated with triple compared with dual oral antiplatelet therapy 16 -19 as well as why cilostazol is particularly efficacious in diabetic patients. 20 -23 Inhibition of platelet P2Y 12 receptor signalling with clopidogrel is pivotal for the prevention of thrombotic complications in patients with acute coronary syndromes and/or undergoing PCI, also in patients with diabetes mellitus. 31 -33 However, despite the clinical benefit associated with clopidogrel treatment, diabetic patients continue to have a higher risk of ischaemic events, as well as stent thrombosis, compared with non-diabetics. 8 -14,31,32 This may be attributed, at least in part, to the greater prevalence of inadequate P2Y 12 inhibition achieved with recommended regimens of clopidogrel in diabetic patients. 1 -2,4 Numerous investigations have shown inadequate platelet inhibition in clopidogrel-treated patients to be associated with a higher risk of atherothrombotic complications, also in T2DM patients. 6, 34 These findings have led to hypothesize that more potent P2Y 12 inhibition may be more beneficial, particularly in high-risk patients. The prognostic implications of achieving more potent P2Y 12 inhibition in high-risk patients has been recently demonstrated in the TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel -Thrombolysis in Myocardial Infarction) trial in which treatment with prasugrel led to better clinical outcomes, including reduced stent thrombosis rates, compared with clopidogrel; 35 the magnitude of this benefit was greatest in diabetic patients, the subgroup in which the clinical efficacy of prasugrel was not offset by increased bleeding. 35 Numerous factors are responsible for suboptimal clopidogrelinduced antiplatelet effects in T2DM patients, among which abnormalities of intracellular cAMP levels play a contributing Cilostazol and platelet function in diabetes mellitus role. 1 -4,8 -10 In vitro studies have shown that insulin reduces platelet aggregation by inhibiting the P2Y 12 pathway. 36 In fact, human platelets are targets of insulin, which interacts with its own receptor on the platelet surface and leads to loss of G i activity. 9, 36 This reduces cAMP suppression leading to an increase in cAMP levels, thus inhibiting P2Y 12 signalling and reducing platelet reactivity. However, platelets of T2DM patients have decreased sensitivity to insulin leading to lower cAMP levels and reduced P2Y 12 inhibition, which overall leads to increased platelet reactivity. 1 -4 Since enhanced platelet reactivity is pivotal to the recurrence of ischaemic events, more aggressive and tailored antiplatelet treatment regimens may be warranted in T2DM patients. 37 The present study demonstrates that treatment with cilostazol, which exerts its antiplatelet effects by increasing cAMP, enhances P2Y 12 inhibition in these high-risk patients as determined by assays which specifically assess this signalling pathway. On the contrary, there were no effects induced by cilostazol when assessments less specific to evaluate this signalling pathway were used (e.g. LTA using ADP as a sole agonist). The fact that in our study cilostazol did not inhibit ADP-induced aggregation may be attributed to the fact that this is less sensitive than VASP-P to assess P2Y 12 signalling. 6 In addition, diabetic platelets have increased exposure to ADP, which stimulate all purinergic receptors, and the mechanism through which cilostazol exerts its inhibitory effects is not on the platelet surface but downstream 8, 9 ( Figure 2 ). Cilostazol is currently approved by the FDA only for symptomatic relief of claudication pain in patients with peripheral arterial disease and for stroke prevention in Japan. In addition to its effects on platelets, cilostazol increases cAMP levels by means of PDEIII inhibition in endothelial and smooth muscular cells. 15 In Asian countries, cilostazol is used as an antiplatelet agent for secondary prevention of ischaemic events and is often preferred over aspirin or thienopyridines due to its comparable efficacy and more favourable safety profile. 15, 38 Treatment with cilostazol, in fact, has shown to be associated with reduced bleeding compared with other antiplatelet agents. 15, 38 Lower bleeding complications associated with cilostazol have been attributed to its protective effects on endothelial cells. 15, 38, 39 Functional studies have shown cilostazol to have antiplatelet effects similar to that achieved with thienopyridines. 40 In Asian countries, cilostazol has been broadly used in combination with aspirin for the prevention of stent thrombosis in patients undergoing coronary stenting, showing similar efficacy to thienopyridines. 41, 42 Cilostazol also reduces neointimal proliferative reactions following coronary stent implantation, including DESs. 17 -23 In clinical studies, triple antiplatelet therapy has shown to reduce major adverse cardiac events and stent thrombosis compared with dual antiplatelet therapy without increasing the risk of bleeding. 16 -19,23 Of note, cilostazol has shown to be more efficacious in inhibiting neointimal proliferative reactions and reducing adverse clinical events in patients with diabetes. 17 -21,23 These findings underscore the importance of the intraplatelet signalling pathway targeted by cilostazol in these patients. Despite the functional implications of adjunctive treatment with cilostazol, as shown in this study, the use of this antiplatelet agent is accompanied by an elevated prevalence of side effects which often lead to discontinuation of treatment. The rate of treatment discontinuation in this study (15%) was similar to that previously reported. 17 Indeed, it may be argued that initiation of cilostazol therapy with lower doses could have reduced the prevalence of side effects. However, the dose chosen in this study was that used in clinical studies testing the efficacy of triple antiplatelet therapy. 16 -23 Overall, the elevated prevalence of side effects associated with cilostazol support the need for alternative treatment strategies to achieve greater P2Y 12 inhibition. Novel oral P2Y 12 receptor antagonists currently under advanced clinical investigation, which have more potent antiplatelet effects compared with clopidogrel, may represent potential future alternatives to treat these high-risk patients. 6 However, the increased risk of bleeding observed with more potent P2Y 12 inhibition, particularly in specific subgroups, remains of concern. 35, 37, 43 To this extent, the fact that clinical studies have not shown any increase in bleeding risk in patients treated with triple compared with dual antiplatelet therapy is noteworthy. 15 -23 12 inhibition, but in whom bleeding may be of concern. The ever raising apprehension for stent thrombosis in the DES era has currently induced many interventionalists to use triple antiplatelet therapy in their high-risk patients. However, to date, the functional implications of this therapeutic approach has been poorly explored and studies have been limited to Asian populations, which are known to have different sensitivity to antiplatelet agents compared with non-Asian populations. 15 The present study is the first to specifically address the impact of cilostazol on P2Y 12 inhibition in a high-risk clinical scenario composed of patients with T2DM.
Study limitations
The present study did not account for conducting multiple significance tests or for potential correlation among various measures of platelet function. Also, our study was not powered to evaluate the safety and efficacy associated with the use of cilostazol in addition to aspirin and clopidogrel. Since our study did not include a wash-out phase between treatment periods, it may be questioned that carry over effects could have occurred and affected the study results. However, cilostazol is a reversible platelet inhibitor with a short half-life (cilostazol and its active metabolites have apparent elimination half-lives of 11 -13 h). 15 Since platelet function was performed 14 days after crossover, it is improbable that the treatment effects carried over throughout the following phase. In addition, our study hypothesis was confirmed in the within sequence analyses. Ultimately, our study findings cannot be extrapolated to non-diabetic patients who do not have the same dysfunctional status of platelet signalling pathways as diabetics.
